Yao WQ, Ma XY, Wang GH. Clinicopathologic features of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma: A case report and review of literature. World J Gastrointest Oncol 2026; 18(1): 114021 [DOI: 10.4251/wjgo.v18.i1.114021]
Corresponding Author of This Article
Gui-Hua Wang, MD, Professor, Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, No. 1260 Kangliang Street, Liangzhu Street, Hangzhou 311112, Zhejiang Province, China. mamaninghao@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jan 15, 2026 (publication date) through Jan 12, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Yao WQ, Ma XY, Wang GH. Clinicopathologic features of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma: A case report and review of literature. World J Gastrointest Oncol 2026; 18(1): 114021 [DOI: 10.4251/wjgo.v18.i1.114021]
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 114021 Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.114021
Clinicopathologic features of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma: A case report and review of literature
Wan-Qi Yao, Xin-Yi Ma, Gui-Hua Wang
Wan-Qi Yao, Gui-Hua Wang, Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 311112, Zhejiang Province, China
Xin-Yi Ma, Department of Pathology, Pathological Diagnosis Center of Dian Diagnostic Technology Group Co., Hangzhou 311112, Zhejiang Province, China
Author contributions: Yao WQ obtained all the required data and drafted the article after literature review; Ma XY responsible for performing immunohistochemical staining; Wang GH critically revised the article and approved the final version of the article.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this article and any accompanying data.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gui-Hua Wang, MD, Professor, Department of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, No. 1260 Kangliang Street, Liangzhu Street, Hangzhou 311112, Zhejiang Province, China. mamaninghao@163.com
Received: September 11, 2025 Revised: November 2, 2025 Accepted: December 1, 2025 Published online: January 15, 2026 Processing time: 123 Days and 17 Hours
Abstract
BACKGROUND
SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is a highly aggressive tumor, and spontaneous splenic rupture (SSR) as its presenting manifestation is rarely reported among pancreatic malignancies.
CASE SUMMARY
We herein report a rare case of a 59-year-old female who presented with acute left upper quadrant abdominal pain without any history of trauma. Abdominal imaging demonstrated a heterogeneous splenic lesion with hemoperitoneum, raising clinical suspicion of SSR. Emergency laparotomy revealed a pancreatic tumor invading the spleen and left kidney, with associated splenic rupture and dense adhesions, necessitating en bloc resection of the distal pancreas, spleen, and left kidney. Histopathology revealed a biphasic malignancy composed of moderately differentiated pancreatic ductal adenocarcinoma and an undifferentiated carcinoma with rhabdoid morphology and loss of SMARCB1 expression. Immunohistochemical analysis confirmed complete loss of SMARCB1/INI1 in the undifferentiated component, along with a high Ki-67 index (approximately 80%) and CD10 positivity. The ductal adenocarcinoma component retained SMARCB1/INI1 expression and was positive for CK7 and CK-pan. Transitional zones between the two tumor components suggested progressive dedifferentiation and underlying genomic instability. The patient received adjuvant chemotherapy with gemcitabine and nab-paclitaxel and maintained a satisfactory quality of life at the 6-month follow-up.
CONCLUSION
This study reports a rare case of SMARCB1/INI1-deficient undifferentiated rhabdoid carcinoma of the pancreas combined with ductal adenocarcinoma, presenting as SSR - an exceptionally uncommon initial manifestation of pancreatic malignancy.
Core Tip: SMARCB1-deficient undifferentiated rhabdoid carcinoma of the pancreas represents a highly aggressive and rare neoplasm. This study suggests that aggressive multimodal therapy, including surgical resection and chemotherapy, may prolong survival in selected patients; however, the overall prognosis remains poor. Given its distinct molecular characteristics and potential resistance to standard therapies, further research into targeted treatment approaches and prospective clinical studies is urgently warranted.
